(Press-News.org) Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease worsening compared with those who received SBRT alone, according to new clinical trial results from UCLA Health Jonsson Comprehensive Cancer Center researchers.
Findings from the trial, presented today at the 2025 American Society for Radiation Oncology Annual Meeting in San Francisco, showed that men who received the radioligand drug went a median of 17.6 months without disease progression, compared with 7.4 months for those who received SBRT alone. This translated into a significant delay in the start of hormone therapy, which is often used to treat recurrent disease.
“This is the first randomized trial to show that PSMA-targeting radioligand can significantly delay progression when added to metastasis-directed radiation,” said Dr. Amar Kishan, executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA and first author of the study. “It gives patients more time before needing hormonal therapy, which can carry significant side effects such as fatigue and bone loss. Avoiding or delaying hormonal therapy consistently benefits quality of life. Moreover, the trial results establish that radioligand therapy agents, which thus far have only been studied in more advanced disease, have a role to play earlier in the disease course.”
Prostate cancer is the second most common cancer among men worldwide. For some, the disease returns years after initial treatment in only a handful of new lesions, a stage known as oligorecurrent disease.
SBRT has become an increasingly common approach for treating these cases, targeting the visible lesions while sparing surrounding healthy tissue. While the approach can delay progression and postpone the need for hormone therapy, most men eventually relapse, often because of microscopic disease too small to detect on imaging scans. Radioligand therapy, which precisely delivers radiation to cancer cells while minimizing harm to healthy tissues, may help address this hidden disease.
The phase 2 study, called the LUNAR trial, explored whether adding a radioactive drug called PNT2002 — a molecule that specifically targets PSMA, a protein highly expressed on the surface of prostate cancer cells — before SBRT could help control these hidden tumors.
“This trial is especially exciting because it showcases the full potential of PSMA-based theranostics technologies,” said senior author of the study Dr. Jeremie Calais, director of the Ahmanson Translational Theranostics Division’s clinical research program and associate professor at the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA. “We leveraged PSMA PET imaging technology to guide SBRT targeting, which is more precise than other imaging methods. And we combined it with PSMA radioligand therapy to treat PSMA expressing sites of disease, both the ones visible by PET but also the microscopic sites too small to be detected by PET.”
To test this hypothesis, the researchers enrolled 92 men with recurrent prostate cancer into the trial and split them at random into two groups. One got SBRT alone, the other got two doses of 177Lu-PNT2002 drug first, then SBRT. The team tracked patients with regular PSA blood tests and PSMA PET scans to see how long they stayed free of cancer progression.
They found adding 177Lu-PSMA before SBRT more than doubled progression-free survival, extending it from 7.4 months to 17.6 months, reducing the risk of cancer returning, the need for hormone therapy, or death by 63%. These benefits were seen across all patient subgroups, regardless of disease stage or the number of lesions, with minimal side effects. Additionally, men in the combination arm went a median of 24.3 months before starting hormonal therapy, compared with 14.1 months in the SBRT-only group.
The team also identified biological markers that may help predict which patients will benefit most from treatment. A stronger immune response after SBRT, measured by T cell receptor changes, was linked to better outcomes, and a set of 20 genes associated with immune function and DNA repair helped define patients at higher or lower risk of progression.
Despite the clear benefit of adding 177Lu-PNT2002 to SBRT, 64% of men still experienced disease progression, underscoring that microscopic cancer remains a major challenge, the researchers noted.
“This is an important proof of principle,” said Kishan, who is also the co-director of the cancer molecular imaging, nanotechnology and theranostics program at the UCLA Health Jonsson Comprehensive Cancer Center. “It suggests we may be able to intervene earlier with radioligand therapy and meaningfully change the course of disease. And, importantly, we didn’t see significantly worse side effects with the addition of the drug. Further research is needed to track longer-term outcomes, and we will also be actively looking at other ways of optimizing response rates.”
“This work is a great example of true collaboration between radiation oncology and nuclear medicine, leveraging theranostics at its best, a mix of imaging and therapy,” Calais added.
Other UCLA authors include Luca F. Valle, Holly Wilhalme, Carol Felix, Rejah Nabong, Jesus E. Juarez-Casillas, Kevin Flores, Vinicius Ludwig, Mariko Nakayama, Zachary Ells, Magnus Dahlbom, Michael Lauria, Catherine Meyer, Joanne B. Weidhaas, Donatello Telesca, Kristen McGreevy, Nicholas G. Nickols, Danielle Karasik, Sophia Parmisano, T. Vincent Basehart, Wayne Brisbane, Leonard Marks, Matthew B. Rettig, Robert E. Reiter, Paul C. Boutros, Martin Allen-Auerbach, Johannes Czernin and Michael L. Steinberg. A full list of authors can be found in the study.
The study was funded by Lantheus.
END
ASTRO: New therapy delays progression of recurrent prostate cancer
Adding PSMA-targeting radioligand therapy to stereotactic body radiotherapy more than doubled progression-free survival in men with recurrent prostate cancer
2025-09-28
ELSE PRESS RELEASES FROM THIS DATE:
Low-dose radiation therapy offers substantial relief to people with painful knee osteoarthritis
2025-09-28
SAN FRANCISCO, September 28, 2025 — A single course of low-dose radiation therapy may provide a safe and effective alternative treatment option for people with painful knee osteoarthritis according to a new randomized, placebo-controlled clinical trial.
The study showed patients with mild to moderate knee osteoarthritis reported significant reductions in pain and improved physical function in the four months after receiving the low dose of radiation, which was just a small fraction of what’s used to treat cancer. Because the study included a control group with simulated treatment, the researchers could distinguish ...
Radiopharmaceutical added to stereotactic radiation delays prostate cancer progression in patients with limited metastatic disease
2025-09-28
SAN FRANCISCO, September 28, 2025 — A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.
The phase II LUNAR trial is the first randomized study to show that a treatment established for later-stage prostate cancer can delay progression and defer hormone therapy when added to high-precision radiation ...
First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer
2025-09-28
SAN FRANCISCO, September 28, 2025 — A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery — the first predictive biomarker in this setting.
In the first prospective, randomized trial to validate a predictive gene expression test for hormone therapy in prostate cancer, patients with a prostate tumor subtype known as luminal B had much lower risks of recurrence and metastasis when radiation was complemented by apalutamide, a type of hormone therapy. Patients without this tumor subtype, however, saw no improvement. ...
Specialised singing programmes can improve the symptoms and quality of life of people with lung disease
2025-09-28
Singing can improve the quality of life of people with lung disease and help reduce their symptoms, according to a gold-standard randomised-controlled trial presented at the European Respiratory Society Congress in Amsterdam, the Netherlands [1].
The study was presented by Professor Natasha Smallwood from Monash University, Melbourne, Australia.
Professor Smallwood told the Congress: “Chronic breathlessness is a common and highly distressing symptom for people with chronic obstructive pulmonary disease and interstitial lung disease. Yet there is a lack ...
Children with asthma who use at-home monitoring are half as likely to need hospital care
2025-09-28
Children with asthma who use at-home monitoring are around half as likely to visit the emergency department or be hospitalised, compared to those who only receive care from their medical team, according to research presented at the European Respiratory Society (ERS) Congress in Amsterdam, the Netherlands [1]. Remote monitoring also helped keep children’s symptoms under control.
At-home monitoring involved children and their families using an app approximately once a month to answer questions ...
Combination inhaler reduces asthma attacks in children by almost half
2025-09-28
Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated.
In the first randomised controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be more effective than salbutamol, the current standard for asthma symptom relief in children, with no additional safety concerns.
The results show that using a single 2-in-1 anti-inflammatory reliever inhaler – ...
Low-cost drug shows promise for patients with life threating respiratory infections
2025-09-28
A widely available and affordable drug has been shown to be effective in treating seriously ill COVID-19 patients, according to a new international study led by researchers at the Australian National University (ANU) in collaboration with King’s College London.
The study analysed data from almost 500 patients hospitalised with COVID-19 across six countries. Patients who inhaled heparin were half as likely to require ventilation and had a significantly lower risk of dying compared with those receiving standard care.
Heparin, a drug traditionally injected to treat blood clots, was tested in this study in an inhaled form, targeting the lungs directly. As well as acting as an anticoagulant, ...
Emergency medicine workers report job satisfaction, though burnout and staff retention remain major problems
2025-09-27
Vienna, Austria: One of the largest international surveys into job satisfaction among emergency department workers has revealed that while the majority found their work satisfying and rewarding, there are still many areas where improvements are needed, according to research presented at the European Emergency Medicine Congress today (Sunday) [1]. The paper, “Global Job Satisfaction Among Emergency Medicine Professionals: Results from the 2025 Emergency Medicine Day Survey”, is published today in the European Journal ...
Eating fruit may reduce the effects of air pollution on lung function
2025-09-27
Eating fruit may reduce the effects of air pollution on lung function
Eating fruit may reduce the effects of air pollution on lung function, according to research presented at the European Respiratory Society Congress in Amsterdam, the Netherlands [1].
The study was presented by Pimpika Kaewsri, a PhD student from the Centre for Environmental Health and Sustainability at the University of Leicester, UK.
She explains: “Over 90% of the global population is exposed to air pollution levels that exceed WHO guidelines, and ample ...
Pulp mill waste becomes green solution to remove toxic dyes
2025-09-27
Dyes like Congo red and methyl orange create brightly hued shirts, sweaters and dresses. But these commonly used azo dyes can be toxic, carcinogenic and are hard to remove from wastewater.
David Chem, a University of Arkansas chemical engineering Ph.D. candidate, developed an environmentally friendly solution to remove these dyes using a common byproduct of the pulp and paper industry.
Azo dyes are used in 60-70% of commercial textile production. The dyes dissolve easily in water and resist biodegradation, which makes them an environmental hazard. ...
LAST 30 PRESS RELEASES:
Study finds altering one area of the brain could rid alcohol withdrawal symptoms
Firstborn behavioral problems impact sibling relationships
Study first to show if nesting heat affects sea turtle hatchling ‘IQ’
Craig Newmark Philanthropies awards grant to CIAS Community Cybersecurity Clinic
ESA's Gaia telescope discovers our galaxy’s great wave
Binghamton University named one of the nation’s best colleges by US News & World Report
Machine learning sharpens earthquake risk assessment maps for Tokyo
Pediatric investigation study links dietary preferences to childhood asthma in Shanghai
Uncovering EUDAL – An RNA that shields oral cancer from drug therapy
Inexpensive multifunctional composite paves the way to a circular economy
MIT joins giant Magellan telescope international consortium
Retraining after a lapse in endurance exercise adds to muscle gains, study finds
PLOS announces a new publishing agreement in India
Touch sensor of the carnivorous plant Venus flytrap revealed
Mix insect, plant, and cultivated proteins for healthier, greener, tastier food, say experts
Far side of the moon may be colder than the near side
Societal inequality linked to structural brain changes in children
Scientists read mice’s ‘thoughts’ from their faces
Newly released dataset BIRDBASE tracks ecological traits for 11,000 birds
A new analytical tool to optimize the potency and selectivity of drugs
Psilocybin may present unique risks during the postpartum period
Immune cell ‘signatures’ could help guide treatment for critically ill patients
USC Stem Cell-led study generates authentic embryonic stem cell from birds
Medicaid work requirements have not boosted insurance coverage or employment
Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis
Experts warn federal cuts may extinguish momentum in tobacco control
The insomnia trade-off
Natural antimicrobial drugs found in pollen could help us protect bee colonies from infection
Why mamba snake bites worsen after antivenom
Biogas slurry boosts biochar’s climate benefits by reshaping soil microbes
[Press-News.org] ASTRO: New therapy delays progression of recurrent prostate cancerAdding PSMA-targeting radioligand therapy to stereotactic body radiotherapy more than doubled progression-free survival in men with recurrent prostate cancer